FDA Aims To Up Transparency By Making Panel Materials Public Sooner
Executive Summary
FDA will post advisory committee briefing materials on its Web site at least two business days in advance of meetings, doubling the current lead time in an effort to enhance transparency, according to a 1draft guidance released last week
You may also be interested in...
FDA Offers Criteria For Convening Advisory Committees In Draft Guidance
FDA certainly has had its fair share of controversy in recent years, and now the agency is embracing controversy as a way to guide decisions about whether an issue is worthy of an advisory committee review
FDA Offers Criteria For Convening Advisory Committees In Draft Guidance
FDA certainly has had its fair share of controversy in recent years, and now the agency is embracing controversy as a way to guide decisions about whether an issue is worthy of an advisory committee review
Draft Conflict Of Interest Policy Affects Status Of Many FDA Cmte. Members
A "significant fraction" of current FDA advisory committee members' eligibility to vote and participate in meetings would be affected by a revised conflict of interest policy, FDA said